Medically reviewed by Drugs.com. Last updated on Oct 12, 2020.
Generic name: Neisseria Meningitidis Group A Polysaccharide Antigen, A 50ug in 0.5mL, Neisseria Meningitidis Group C Polysaccharide Antigen, A 50ug in 0.5mL, Neisseria Meningitidis Group Y Polysaccharide Antigen, A 50ug in 0.5mL, Neisseria Meningitidis Group W-135 Polysaccharide Antigen, A 50ug in 0.5mL;
Dosage form: injection
The lyophilized vaccine should be a white or off-white color to a light beige color. The diluent used for reconstitution is a clear liquid.
Using a suitable size syringe, withdraw the supplied diluent (0.6 mL for single-dose presentation and 6.0 mL for multidose presentation) and inject into the vial containing the lyophilized vaccine. Swirl the vial until the vaccine is thoroughly dissolved. When reconstituted, the vaccine should be a clear, colorless liquid.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exist, the vaccine should not be administered.
Withdraw and administer a 0.5 mL dose of Menomune – A/C/Y/W-135 vaccine by subcutaneous injection.
Vaccine supplied in single dose vials should be used immediately after reconstitution.
Vaccine supplied in multidose vials may be used for up to 35 days after reconstitution if stored at 2° to 8°C (35° to 46°F). [See How Supplied/Storage and Handling (16.2).]
Primary immunization with Menomune – A/C/Y/W-135 vaccine consists of a single 0.5mL dose administered subcutaneously. The preferred site of administration is the deltoid region.
The ACIP (Advisory Committee on Immunization Practices) has specfic recommendations for use of meningococcal vaccines. (1) (2) (3)
More about Menomune A / C / Y / W-135 (meningococcal polysaccharide vaccine)
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.